We can now prevent HIV transmissions and deaths — progress impossible without investments from the U.S. government ...

The Conference on Retroviruses and Opportunistic Infections 2025 opened with a session dedicated to informing attendees about ...

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Nearly half of all new cases in 2022 were in the South. "The frustrating part is we have the tools now to stop it." ...

The United States’ shutdown of HIV/Aids funding may harm global Aids programmes irreparably, jeopardising millions of lives ...

Allies in Hope, formerly AIDS Foundation Houston, hosted the 36th Annual Walk to End HIV at Sam Houston Park in downtown ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

Sustained focus and resources aimed at helping the most socially and economically vulnerable are essential, too — as the ...

Accurate and ethical journalism on HIV/AIDS plays a vital role in shaping public perceptions, encouraging behavioral change, and raising awareness. Misinformation or vague reporting, however, can ...

Debates over tuberculosis reporting began in the late 19th century, when the bacterial infection was reframed not as a disease of the elite but of the urban poor. New York City was the first in the ...

March is a significant month for women's health, observing International Women's Day and National Women's HIV/AIDS Awareness ...

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...